Thirteen cases with unresectable primary hepatocellular carcinoma were treated by administering SMANCS/LIPIODOL into the common or proper hepatic artery and followed for over three years. Results were as follows ;
1) Changes in liver function after the administration of SMANCS/LIPIODOL were milder than those after the administration of TAE.
2) The survival rates at one year, two years and three years were 53.8%, 15.4% and 7.6%, respectively.
